Arestat™ comprises two fundamentally different aspects of
our platform stabilization technology. Both utilize excipients
and buffers approved by the FDA and EMEA in an unconventional
manner to achieve the desired stability.
Both platform technologies are available for licensing for applications involving
therapeutic proteins, vaccines, medical devices and diagnostics.
Formulations developed by Arecor through the application of
Arestat-R™ or Arestat-T™ can be commercialised
by their partners through the acquisition of a commercial
license. The terms and conditions agreed in the license
allow Arecor’s partners the opportunity to exploit the
formulation(s) developed using Arestat™ for
applications specifically defined in the commercial
agreement. Under the terms of the commercial agreement
Arecor’s partners are at liberty to file composition of
matter patents to protect their proprietary formulations.